胃肠道腺癌KRAS突变分析揭示部位特异性突变特征
该研究整合44项研究测序数据,分析7382例腺癌中2523个KRAS突变,发现胃肠道腺癌KRAS突变频率呈显著区域差异,胰腺腺癌最高达94.9%,食管和胃腺癌仅5.4%和8.7%;错义突变模式具部位特异性,c.35G>T(p.G12V)和c.34G>C(p.G12R)富集于胰腺原发,密码子13及非12/13改变富集于胃原发;食管和胃腺癌中转换突变富集。
要点
- 胰腺腺癌KRAS突变频率最高达94.9%,食管和胃腺癌仅5.4%和8.7%。
- c.35G>T(p.G12V)和c.34G>C(p.G12R)富集于胰腺原发,对胰腺腺癌特异性98.9%。
- 密码子13及非12/13改变富集于胃原发,对胰腺腺癌特异性93.2%。
核心结论
- KRAS突变频率和错义突变模式在胃肠道腺癌中呈部位特异性,有助于鉴别形态和免疫组化重叠的转移性腺癌的原发部位。
- 食管和胃腺癌中转换突变富集,提示慢性炎症在前肠腺癌发病中的作用。
研究设计与样本
- 整合44项独立研究的测序数据,评估7382例腺癌中的2523个KRAS突变,覆盖食管、胃、壶腹部、胆道系统、胰腺和结肠。
- 采用本机构验证队列验证趋势。
主要发现
- 胰腺腺癌KRAS突变频率最高达94.9%,食管和胃腺癌分别为5.4%和8.7%。
- c.35G>T(p.G12V)和c.34G>C(p.G12R)富集于胰腺原发,对胰腺腺癌特异性98.9%,阴性预测值93.6%。
- 密码子13及非12/13改变富集于胃原发,对胰腺腺癌特异性93.2%,阴性预测值92.93%。
- 食管和胃腺癌显示转换突变富集,其他部位分布均等。
关键数值与推荐
- 胰腺腺癌KRAS突变频率最高达94.9%。
- 食管和胃腺癌KRAS突变频率分别为5.4%和8.7%。
- c.35G>T(p.G12V)和c.34G>C(p.G12R)对胰腺腺癌特异性98.9%,阴性预测值93.6%。
- 密码子13及非12/13改变对胰腺腺癌特异性93.2%,阴性预测值92.93%。
临床怎么用
- KRAS突变分析可辅助鉴别形态和免疫组化重叠的胃肠道腺癌的原发部位。
- 特定KRAS突变模式(如p.G12V/p.G12R富集胰腺,密码子13/非12/13改变富集胃)可提示原发灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adenocarcinomas of the luminal gastrointestinal tract and pancreatobiliary system often show histologic and immunohistochemical overlap, making delineation of the primary site in a metastatic setting difficult. Previous studies have shown that site-specific missense mutations in the oncogene KRAS could be used in conjunction with immunohistochemistry to differentiate metastatic pancreatic adenocarcinoma from primary lung adenocarcinoma. In this study, we assessed the patterning of KRAS mutations across sites in the gastrointestinal and pancreatobiliary system. By integrating sequencing data from 44 separate studies, we assessed 2523 KRAS mutations in 7382 distinct cases of adenocarcinoma, including those from the esophagus, stomach, ampulla, biliary system, pancreas, and colon. We found that gastrointestinal adenocarcinomas demonstrate a marked regional variation in the frequency of KRAS mutations, with the most frequent KRAS mutation observed in pancreatic adenocarcinoma (up to 94.9%), whereas the frequency is much lower in adenocarcinomas from the esophagus and stomach (5.4% and 8.7%, respectively). Intriguingly, the pattern of missense mutations showed site specificity as well, with c.35G>T (p.G12V) and c.34G>C (p.G12R) mutations enriched in pancreatic primaries and codon 13 and non-codon 12/13 alterations enriched in gastric primaries (specificity of 98.9% and 93.2%, respectively, with a negative predictive value of 93.6% and 92.93% against pancreatic adenocarcinoma). Furthermore, we found that esophageal and gastric adenocarcinomas show an enrichment in transitional mutations, whereas other sites showed an equal distribution. Importantly, the examination of a validation cohort from our own institution revealed similar trends. These findings indicate that, in addition to providing therapeutic and diagnostic information, KRAS mutational analysis may also prove useful in delineating the site of origin in gastrointestinal adenocarcinomas that share morphologic and immunohistochemical overlap. Moreover, transitional mutations are more frequent in esophageal and gastric adenocarcinomas, reiterating the role of chronic inflammation in the pathogenesis of foregut adenocarcinomas.
引用
- Wang L, Saeedi BJ, Mahdi Z, et al. Analysis of KRAS Mutations in Gastrointestinal Tract Adenocarcinomas Reveals Site-Specific Mutational Signatures. Mod Pathol. 2023. PMID: 36853786. doi:10.1016/j.modpat.2022.100014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。